{"entity":{"id":"nct02159066","kind":"trial","name":"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma","aka":[],"tldr":"A phase 2 trial of Infigratinib and Capmatinib in Melanoma, run by Pfizer, completed.","summary":"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma is a phase 2 interventional study registered as NCT02159066 by Pfizer, with 158 participants recorded, started 2014-07-23 and reaching its primary completion in 2023-01-10. Interventions recorded: LGX818, MEK162, LEE011, BGJ398, BKM120, INC280. Conditions recorded: Melanoma.\n\nLinked to the drug Infigratinib because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02159066","url":"https://clinicaltrials.gov/study/NCT02159066"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","advanced-melanoma","braf-v600-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["infigratinib","capmatinib"],"companies":["pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02159066","phase":"2","setting":"The LOGIC 2 Trial A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma.","sponsor":"Pfizer","started":"2014-07-23","startedType":"actual","yearReported":2024,"enrolled":158,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall Response Rate (ORR): Part II","primary":true,"unit":"%","arms":[{"name":"Part II: Encorafenib + Binimetinib + Ribociclib","n":38,"value":2.6,"note":"95% CI 0.1 to 13.8; Figures from the ClinicalTrials.gov results section (first posted 2024-03-05), not from a publication"},{"name":"Part II: Encorafenib + Binimetinib + Infigratinib","n":1,"value":0,"note":"95% CI NA to NA"},{"name":"Part II: Encorafenib + Binimetinib + Capmatinib","n":13,"value":0,"note":"95% CI 0.0 to 24.7"},{"name":"Part II: Encorafenib + Binimetinib + Buparlisib","n":6,"value":0,"note":"95% CI 0.0 to 45.9"}],"source":"https://clinicaltrials.gov/study/NCT02159066?tab=results"},{"endpoint":"Overall Survival (OS): Part II","unit":"months","arms":[{"name":"Part II: Encorafenib + Binimetinib + Ribociclib","n":38,"value":10.4,"note":"95% CI 6.0 to 16.7; Figures from the ClinicalTrials.gov results section (first posted 2024-03-05), not from a publication"},{"name":"Part II: Encorafenib + Binimetinib + Infigratinib","n":1,"value":20.8,"note":"95% CI NA to NA"},{"name":"Part II: Encorafenib + Binimetinib + Capmatinib","n":13,"value":5.6,"note":"95% CI 1.7 to NA"},{"name":"Part II: Encorafenib + Binimetinib + Buparlisib","n":6,"value":2.5,"note":"95% CI 0.4 to NA"}],"source":"https://clinicaltrials.gov/study/NCT02159066?tab=results"},{"endpoint":"Progression-Free Survival (PFS): Part I","unit":"months","arms":[{"name":"Part I: Encorafenib + Binimetinib (Naive)","n":75,"value":11.1,"note":"95% CI 8.1 to 15.0; Figures from the ClinicalTrials.gov results section (first posted 2024-03-05), not from a publication"},{"name":"Part I: Encorafenib + Binimetinib (Non-naive)","n":83,"value":3.3,"note":"95% CI 2.1 to 4.7"}],"source":"https://clinicaltrials.gov/study/NCT02159066?tab=results"}]},"route":"/trials/nct02159066/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"capmatinib","kind":"drug","name":"Capmatinib","route":"/drugs/capmatinib/"},{"id":"infigratinib","kind":"drug","name":"Infigratinib","route":"/drugs/infigratinib/"}],"company":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}]}}